tjh-v37i2

More documents

Recommendations

Info

Çiftçiler R, et al: The Impact of Early Versus Late Platelet and Neutrophil RecoveryTurk J Hematol 2020;37:116-120used as prognostic indicators in countries with limited laboratoryfacilities. Our results support the impression that an acceleratedplatelet and neutrophil recovery following chemotherapy couldbe accepted as a promising sign of good prognosis and thusgood future response to therapy in AML. The results of thisstudy are important for prediction of the prognosis of newlydiagnosed AML patients.EthicsEthics Committee Approval: All ethical considerationswere strictly followed in accordance with the 1964 HelsinkiDeclaration. As standard care/action of the hospitals of theHacettepe Medical School, it has been recognized from thepatient records that all of the studied patients had giveninformed consent at the time of hospitalization and before theadministration of chemotherapy and other relevant diagnostic/therapeutic standards of care.Informed Consent: All of the studied patients gave informedconsent at the time of admission to the hospital.Authorship ContributionsSurgical and Medical Practices: R.Ç.; Concept: Y.B.; Design:H.D.; Data Collection or Processing: R.Ç., Ü.Y.M.; Analysis orInterpretation: Y.B., O.Ö., N.S.; Literature Search: İ.C.H., S.A.;Writing: R.Ç.Conflict of Interest: The authors of this paper have no conflictof interests, including specific financial interests, relationships,and/or affiliations relevant to the subject matter or materialsincluded.Financial Disclosure: The authors declared that this studyreceived no financial support.References1. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acutemyeloid leukemia. Crit Rev Oncol Hematol 2008;66:181-193.2. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T,Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T,Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF,Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AMLin adults: 2017 ELN recommendations from an international expert panel.Blood 2017;129:424-447.3. Liersch R, Müller-Tidow C, Berdel WE, Krug U. Prognostic factors for acutemyeloid leukaemia in adults-biological significance and clinical use. Br JHaematol 2014;165:17-38.4. Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, OssenkoppeleGJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, AppelbaumFR, Estey EH. Resistance prediction in AML: analysis of 4601 patientsfrom MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.Leukemia 2015;29:312-320.5. Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S,Kantarjian H, Estey E. Blood counts at time of complete remission provideadditional independent prognostic information in acute myeloid leukemia.Leuk Res 2008;32:1505-1509.6. Malkan UY, Gunes G, Isik A, Eliacik E, Etgul S, Aslan T, Balaban MS,Haznedaroglu IC, Demiroglu H, Goker H, Ozcebe OI, Sayınalp N, Aksu S,Buyukasik Y. Rebound thrombocytosis following induction chemotherapyis an independent predictor of a good prognosis in acute myeloid leukemiapatients attaining first complete remission. Acta Haematol 2015;134:32-37.7. Gonen C, Haznedaroglu IC, Aksu S, Koca E, Göker H, Büyükaşik Y, Sayinalp N,Ozcebe O, Dündar S. Endogenous thrombopoietin levels during the clinicalmanagement of acute myeloid leukaemia. Platelets 2005;16:31-37.8. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY,O’Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A,Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/IIstudy of combination therapy with sorafenib, idarubicin, and cytarabine inyounger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-1862.9. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, BurnettAK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T,Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, LöwenbergB, Bloomfield CD; European LeukemiaNet. Diagnosis and management ofacute myeloid leukemia in adults: recommendations from an internationalexpert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, CarbonePP. Toxicity and response criteria of the Eastern Cooperative OncologyGroup. Am J Clin Oncol 1982;5:649-656.11. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, TallmanMS. Early peripheral blood blast clearance during induction chemotherapyfor acute myeloid leukemia predicts superior relapse-free survival. Blood2007;110:4172-4174.12. Vainstein V, Buckley SA, Shukron O, Estey EH, Abkowitz JL, Wood BL, WalterRB. Rapid rate of peripheral blood blast clearance accurately predictscomplete remission in acute myeloid leukemia. Leukemia 2014;28:713.13. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A,Sauerland MC, Berdel W, Buchner T, Hiddemann W. Early blast clearance byremission induction therapy is a major independent prognostic factor forboth achievement of complete remission and long-term outcome in acutemyeloid leukemia: data from the German AML Cooperative Group (AMLCG)1992 Trial. Blood 2003;101:64-70.14. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, SchellongG. Definition of a standard-risk group in children with AML. Br J Haematol1999;104:630-639.15. Creutzig U, Zimmermann M, Dworzak MN, Gibson B, Tamminga R,Abrahamsson J, Ha SY, Hasle H, Maschan A, Bertrand Y, Leverger G, vonNeuhoff C, Razzouk B, Rizzari C, Smisek P, Smith OP, Stark B, ReinhardtD, Kaspers GL. The prognostic significance of early treatment response inpediatric relapsed acute myeloid leukemia: results of the internationalstudy Relapsed AML 2001/01. Haematologica 2014;99:1472-1478.16. Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, ItoS, Tachibana T, Hagihara M, Matsumoto K, Koharazawa H, Taguchi J, TomitaN, Fujimaki K, Fujita H, Fujisawa S, Ogawa K, Ishigatsubo Y. Hyper-recoveryof platelets after induction therapy is a predictor of relapse-free survival inacute myeloid leukemia. Leuk Lymphoma 2017;58:104-109.17. Ciftciler R, Demiroglu H, Buyukasık Y, Aksu S, Goker H. Impact of bloodcount recovery-based complete remission before allogeneic hematopoieticstem cell transplantation on survival in patients with acute myeloidleukemia. Clin Lymphoma Myeloma Leuk 2019;19:e205-e212.120
IMAGES IN HEMATOLOGYDOI: 10.4274/tjh.galenos.2019.2019.0134Turk J Hematol 2020;37:121-122A Rare Chromosomal Abnormality in Chronic LymphocyticLeukemia: t(13;13)Kronik Lenfositik Lösemide Nadir Bir Kromozomal Anomali: t(13;13)Akbar Safaei 1 , Ahmad Monabati 1,3 , Moeinadin Safavi 1,21Shiraz University of Medical Sciences Molecular Pathology and Cytogenetic Section, Medical Faculty, Department of Pathology, Shiraz, Iran2Tehran University of Medical Sciences Medical Faculty, Department of Pathology, Tehran, Iran3Shiraz University of Medical Sciences, Hematopathology Research Center, Shiraz, IranFigure 1. Peripheral blood culture with TPA revealed t(13;13) (q14;q32).The patient was a 67-year-old man with peripheral bloodlymphocytosis. The patient’s complete blood count revealedhemoglobin of 12.2 g/dL, white blood cell count of 22,000/µL,and platelet count of 124,000/µL. The differential count forwhite blood cells was as follows: neutrophils, 10%; lymphocytes,86%; and monocytes, 4%. Absolute lymphocyte count was18,920/µL. Flow cytometry of peripheral blood revealed 86%lymphocytes, which were positive for CD19, CD79b, CD20 (dim),CD5, CD23, and CD45, but they were negative for FMC7 andCD38. Blood culture with phorbol 12-myristate 13-acetate (TPA)and subsequent Giemsa banding revealed t(13;13)(q14;q32)[8]/46,XY[12] (Figure 1).Structural aberrations of the long arm of chromosome13,t/del(13q) account for 20% of all chromosomal abnormalitiesin chronic lymphocytic leukemia [1]. This rate is even higher when©Copyright 2020 by Turkish Society of HematologyTurkish Journal of Hematology, Published by Galenos Publishing HouseAddress for Correspondence/Yazışma Adresi: Moeinadin Safavi, M.D., Shiraz University of Medical SciencesMolecular Pathology and Cytogenetic Section, Medical Faculty, Department of Pathology, Shiraz, IranE-mail : safavi_moeinadin@yahoo.com ORCID: orcid.org/0000-0002-4042-7506Received/Geliş tarihi: March 29, 2019Accepted/Kabul tarihi: June 11, 2019121
Page 1 and 2:
Volume 37 Issue 2June 2020E-ISSN: 1
Page 4:
Multipl miyelom tedavisi içinETKİ
Page 7 and 8:
Contact InformationEditorial Corres
Page 9 and 10: TURKISH JOURNAL OF HEMATOLOGYINSTRU
Page 11 and 12: important findings should be highli
Page 13 and 14: Full instructions and support are a
Page 15: Letters to the Editor125 Percentage
Page 18 and 19: Fodil M and Zemani F: Inhibitor Dev
Page 24 and 25: RESEARCH ARTICLEDOI: 10.4274/tjh.ga
Page 26 and 27: Okay M, et al: Splenic Marginal Zon
Page 32 and 33: Wang H, et al: Bortezomib-based Reg
Page 40 and 41: Küçükcankurt F, et al: PTEN and
Page 42 and 43: Küçükcankurt F, et al: PTEN and
Page 46 and 47: Li M, et al: Expression Profile of
Page 52 and 53: Paviglianiti A: Metabolic Diseases
Page 54 and 55: Paviglianiti A: Metabolic Diseases
Page 56 and 57: BRIEF REPORTDOI: 10.4274/tjh.galeno
Page 58 and 59: Çiftçiler R, et al: The Impact of
Page 62 and 63: Safaei A, et al: Rare Chromosomal A
Page 64 and 65: Kumar C, et al: Erythroblastic Isla
Page 66 and 67: LETTERS TO THE EDITORTurk J Hematol
show all

tjh-v37i2

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?